Advertisement
Canada markets open in 8 hours 54 minutes

  • S&P/TSX

    21,656.05
    +13.18 (+0.06%)
     

  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • CAD/USD

    0.7272
    +0.0008 (+0.11%)
     

  • CRUDE OIL

    82.87
    +0.18 (+0.22%)
     

  • Bitcoin CAD

    85,240.92
    -2,760.50 (-3.14%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,389.30
    +0.90 (+0.04%)
     

  • RUSSELL 2000

    1,947.95
    -19.53 (-0.99%)
     

  • 10-Yr Bond

    4.5850
    -0.0740 (-1.59%)
     

  • NASDAQ futures

    17,730.75
    +72.25 (+0.41%)
     

  • VOLATILITY

    18.21
    -0.19 (-1.03%)
     

  • FTSE

    7,847.99
    +27.63 (+0.35%)
     

  • NIKKEI 225

    38,162.37
    +200.57 (+0.53%)
     

  • CAD/EUR

    0.6807
    +0.0005 (+0.07%)
     

Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting

Otonomy, Inc.
·3 min read

  • Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss

  • Supportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection program

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Neuroscience 2021 meeting, which is the annual meeting of the Society for Neuroscience (SfN). This meeting will be held virtually November 8-11, 2021 with Preview Days taking place November 3-7 during which registered attendees can preview pre-recorded presentations. Otonomy’s presentations include the previously disclosed positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss, and multiple presentations related to Otonomy’s preclinical programs.

“We are pleased to have the opportunity to review the positive clinical results for OTO-313 and OTO-413 for the broader neuroscience research community during this prestigious conference,” said Alan C. Foster, Ph.D., chief scientific officer of Otonomy. “Our multiple presentations highlight the breadth of our pipeline and provide supportive data for our preclinical programs including OTO-825, a gene therapy for congenital hearing loss, and OTO-510, an otoprotectant for cisplatin-induced hearing loss.”

The following presentations related to Otonomy’s clinical programs will be held during interactive poster sessions occurring from 3:15 to 4:15 p.m. EST on November 8.

ADVERTISEMENT

  • “Initial clinical evaluation of OTO-313 given as a single intratympanic injection in patients with moderate to severe, persistent tinnitus” by Anderson et al.

  • “A first-in-human study of OTO-413, an intratympanic sustained-exposure formulation of BDNF, for the treatment of hearing loss” presented by Victoria Sanchez, Au.D., Ph.D., Assistant Professor of University of South Florida and principal investigator on the study.

All other Otonomy presentations are during interactive poster sessions occurring from 3:30 to 4:30 p.m. EST on November 10.

  • “AAV-mediated gene therapy with OTO-825 rescues hearing loss and cochlear degeneration in two mouse models of GJB2 congenital hearing loss” a joint presentation from Otonomy and Applied Genetics Technology Corporation (AGTC) by Uribe et al.

  • “Local delivery of BDNF (OTO-413) and a selective TrkB agonist (M3) restores hearing function in models of cochlear synaptopathy” by Fernandez et al.

  • “Identification and characterization of OTO-510 as a novel approach to the prevention of cisplatin-induced hearing loss” by Mathur et al.

  • “Novel fab fragments derived from Trk-selective agonist monoclonal antibodies are potent and selective antagonists of the TrkB and TrkC receptors” by Siegel et al.

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
cramsey@spectrumscience.com

Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com